Table 2. Survival according to ITPR2 expression in the primary cohort of 157 CN-AML patients.
| Outcome | All patients, n = 157 | ELN Favorable category | ELN Intermediate-I category | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ITPR2high, n = 78 | ITPR2low, n = 79 | P | ITPR2high, n = 25 | ITPR2low, n = 34 | P | ITPR2high, n = 72 | ITPR2low, n = 50 | P | |
| OS | |||||||||
| Median OS, m | 11.28 (0.07–175.7) | 39.36 (0.13–214.5) | 0.0016 | 27.1 (0.59–163.1) | 61.26 (0.3–214.5) | 0.11 | 10.92 (0.07–175.7) | 33.26 (0.13–198.7) | 0.03 |
| Estimated OS at 3 y. (95% CI) | 0.32 (0.23–0.44) | 0.56 (0.46–0.68) | 0.03 | 0.48 (0.32–0.72) | 0.62 (0.47–0.81) | 0.26 | 0.31 (0.22–0.43) | 0.52 (0.4–0.68) | 0.04 |
| EFS | |||||||||
| Median EFS, m | 8.36 (0.03–148) | 18.37 (0.03–214.5) | 0.0022 | 14.36 (0.03–148) | 39.59 (0.03–214.5) | 0.12 | 8.295 (0.03–148) | 15.23 (0.03–198.7) | 0.02 |
| Estimated EFS at 3 y. (95% CI) | 0.26 (0.18–0.37) | 0.43 (0.33–0.56) | 0.05 | 0.4 (0.25–0.65) | 0.56 (0.42–0.75) | 0.25 | 0.24 (0.16–0.36) | 0.36 (0.25–0.52) | 0.05 |